Review and Prospect of the Lapinized Vaccine C-strain Against Classical Swine Fever

QIU Hua-ji

PDF(440 KB)
PDF(440 KB)
Scientia Agricultura Sinica ›› 2007, Vol. 40 ›› Issue (增刊) : 3358-3362. DOI: 10.3864/j.issn.0578-1752.nykx-200740-3358

Review and Prospect of the Lapinized Vaccine C-strain Against Classical Swine Fever

  • QIU Hua-ji
Author information +
History +

Abstract

The well-known lapinized vaccine Chinese strain (also known as C-strain) against classical swine fever was jointly developed by National Control Institute of Veterinary Bio-products and Pharmaceuticals and Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences in China in the middle 1950s. The major contributors include Drs. Zhou Taichong, Yuan Qingzhi, Fang Shijie, Chen Lingfeng. In the past half a century, the vaccine was proved to be safe and immunogenic in pigs of essentially any age. It was of high efficacy. It provided immunized animals with broad-spectrum, sometimes lifelong, protection, which is contributed by cell-mediated immunity and humoral immunity, against essentially all genotypes or subgenotypes of the virus. The maternal antibodies derived from immunized sows can confer solid protection on their offspring from disease; however, they have been proved to inhibit the successful immunization of C-vaccine. The complete genome of C-strain, together with those of its parent strain and dozens of established and field strains, has been sequenced and annotated. Recently, the reverse genetics system of C-strain has been developed, resulting in several C-strain-derived candidate marker vaccines. Many countries manage to control or even eradicate CSF with the aid of C-strain vaccination. In spite of these efforts, the eradication of the disease worldwide remains a big challenge and needs a long way to go, and provably still resort to genetically modified C-strain. This paper reviews and prospects different aspects of the vaccine, which has stood the test of half a century.

Key words

Swine fever / Lapinized vaccine

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
QIU Hua-ji. Review and Prospect of the Lapinized Vaccine C-strain Against Classical Swine Fever. Scientia Agricultura Sinica. 2007, 40(增刊): 3358-3362 https://doi.org/10.3864/j.issn.0578-1752.nykx-200740-3358

References

[1]中国农业科学院哈尔滨兽医研究所. 建所四十周年科技成果汇编(1948-1988). 1988: 122.
[2]中国农业科学编辑部. 我国农业科学技术发展摘记—畜牧·兽医. 中国农业科学, 1993, 26(6): 89-93.
[3]农牧渔业部科学技术司. 农牧渔业重要科技成果年报, 1984, 6: 175-177.
[4]Terpstra C, Woortmeyer R, Barteling S J. Development and properties of a cell culture produced vaccine for hog cholera based on the Chinese strain. Deutsche Tierarztliche Wochenschrift, 1990, 97(2): 77-79.
[5]Rivero V B, Gualandi G L, Buonavoglia C, Mortarino P. A study on the susceptibility of minipig kidney (MPK) and rabbit kidney (RK13) cell line cultures to the lapinized Chinese strain of hog cholera virus. Microbiologica, 1988, 11(4): 371-378. 
[6]Rivero V B, Gualandi G L, Ferrari M, Boldini M, Buonavoglia C, Mortarino P. The lapinized Chinese strain of hog cholera virus (HCV) previously adapted in minipig kidney (MPK) cell line cultures, would also protect pigs to experimental infection with virulent HCV. Microbiologica, 1990, 13(3): 185-189.
[7]Gualandi G L, Ferrari M, Cardeti G, Boldini M, Buonavoglia C. Protection tests in pigs vaccinated with the lapinized Chinese strain of hog cholera virus (HCV) previously adapted in a minipig kidney (MPK) cell line, to challenge infection with virulent HCV. Microbiologica, 1991, 14(3): 213-217.
[8]Terzic S, Jemersic L, Lojkic M, Madic J, Grom J, Toplak I, Sver L, Valpotic I. Comparison of antibody values in sera of pigs vaccinated with a subunit or an attenuated vaccine against classical swine fever. Veterinary Research Communications, 2003, 27(4): 329-339.
[9]Moormann R J, van Gennip H G, Miedema G K, Hulst M M, van Rijn P A. Infectious RNA transcribed from an engineered full-length cDNA template of the genome of a pestivirus. Journal of Virology, 1996, 70(2): 763-770.
[10]van Gennip H G, van Rijn P A, Widjojoatmodjo M N, Moormann R J. Recovery of infectious classical swine fever virus (CSFV) from full-length genomic cDNA clones by a swine kidney cell line expressing bacteriophage T7 RNA polymerase. Journal of Virological Methods, 1999, 78(1-2): 117-128. 
[11]Widjojoatmodjo M N, van Gennip H G, Bouma A, van Rijn P A, Moormann R J. Classical swine fever virus E(rns) deletion mutants: trans-complementation and potential use as nontransmissible, modified, live-attenuated marker vaccines. Journal of Virology, 2000, 74(7): 2973-2980.
[12]van Gennip H G, van Rijn P A, Widjojoatmodjo M N, de Smit A J, Moormann R J. Chimeric classical swine fever viruses containing envelope protein E(RNS) or E2 of bovine viral diarrhoea virus protect pigs against challenge with CSFV and induce a distinguishable antibody response. Vaccine, 2000, 19(4-5): 447-459.
[13]de Smit A J, Bouma A, van Gennip H G, de Kluijver E P, Moormann R J. Chimeric (marker) C-strain viruses induce clinical protection against virulent classical swine fever virus (CSFV) and reduce transmission of CSFV between vaccinated pigs. Vaccine, 2001, 19(11-12): 1467-1476.
[14]de Smit A J, van Gennip H G, Miedema G K, van Rijn P A, Terpstra C, Moormann R J. Recombinant classical swine fever (CSF) viruses derived from the Chinese vaccine strain (C-strain) of CSF virus retain their avirulent and immunogenic characteristics. Vaccine, 2000, 18(22): 2351-2358.
[15]van Gennip H G, Bouma A, van Rijn P A, Widjojoatmodjo M N, Moormann R J. Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV. Vaccine, 2002, 20(11-12): 1544-1556.
[16]Floegel-Niesmann G. Marker vaccines and companion diagnostic tests for classical swine fever. Developments in Biological Standardization (Basel), 2003, 114: 185-191.
[17]Sato U, Hanaki T, Nobuto K. Attenuation of the hog cholera virus by continuous cell-virus propagation. 3. Growth interference of Newcastle disease virus by attenuated hog cholera virus and its application to virus titration and the neutralization test. Arch Gesamte Virusforsch, 1969, 26(1): 1-10.
[18]Corthier G, Aynaud J M. Comparison of the immune response in serum and bucco-pharyngeal secretions following immunization by different routes with a live hog cholera virus vaccine (Thiverval strain). Annales de Recherches Veterinaires, 1977, 8(2): 159-165.
[19]王在时. 猪瘟防治研究的回顾和展望. 畜禽重大疫病免疫预防研究进展. 北京: 中国农业出版社, 1996: 64-71.
[20]Kaden V, Glaner M. Zum eintritt und zur Dauer der Immunität gegen Schweinepest nach aerogener Immunisierung. Archiv fur Experimentelle Veterinarmedizin (Leipzig), 1982, 36: 593-599.
[21]Lai S S, Chen C S, Huang T H. Roles of protection in pigs given an attenuated hog cholera virus vaccine- LPC- China strain. In: Proceedings of the International Pigs Veterinary Society. Mexico City, 1982: 126.
[22]Biront P, Leunen J, Vandeputte J. Inhibition of virus replication in the tonsils of pigs previously vaccinated with a Chinese strain vaccine and challenged oronasally with a virulent strain of classical swine fever virus. Veterinary of Microbiology, 1987, 14(2): 105-113.
[23]Terpstra C, Woortmeyer R, Barteling S J. Development and properties of a cell culture produced vaccine for hog cholera based on the Chinese strain. Deutsche Tierarztliche Wochenschrift, 1990, 97(2): 77-79.
[24]Dahle J, Liess B. Assessment of safety and protective value of a cell culture modified strain "C" vaccine of hog cholera/classical swine fever virus. Berliner und Munchener Tierarztliche Wochenschrift (Berlin), 1995, 108(1): 20-25.
[25]de Smit A J, Bouma A, van Gennip H G, de Kluijver E P, Moormann R J. Chimeric (marker) C-strain viruses induce clinical protection against virulent classical swine fever virus (CSFV) and reduce transmission of CSFV between vaccinated pigs. Vaccine, 2001, 19(11-12): 1467-1476.
[26]Aynaud J M. Classical Swine Fever and Related Viral Infections. Boston: Martinus Nijhoff, 1988: 165-180.
[27]Kaden V, Lange B. Oral immunisation against classical swine fever (CSF): onset and duration of immunity. Veterinary of Microbiology, 2001, 82: 301-310.
[28]Szent-Ivanyi T. Eradication of classical swine fever in Hungary. In: Proceedings of the CEC Seminar on Hog Cholera Classical Swine Fever and African Swine Fever. Hanover: EUR 5904 EN, 1977: 443-440.
[29]Vandeputte J, Too H L, Ng F K, Chen C, Chai K K, Liao G A. Adsorption of colostral antibodies against classical swine fever, persistence of maternal antibodies, and effect on response to vaccination in baby pigs. Ameican Journal of Veterinary Research, 2001, 62(11): 1805-1811. 
[30]Dewulf J. Epidemiology and control of classical swine fever: experimental assessment of virus transmission and potential benefits of emergency vaccination. Ph.D. Thesis. Universiteit Gent, 2002.
[31]Aynaud J M, Corthier G, Laude H, Galicher C, Gelfi J. Sub-clinical swine fever: a survey of neutralizing antibodies in ther sera of pigs from herds having reproductive failures. Annales de Recherches Veterinaires, 1976, 7(1): 57-64.
[32]Terpstra C, Wensvoort G. The protective value of vaccine-induced neutralising antibody titres in swine fever. Veterinary of Microbiology, 1988, 16(2): 123-128.
[33]Tu C, Lu Z, Li H, Yu X, Liu X, Li Y, Zhang H, Yin Z. Phylogenetic comparison of classical swine fever virus in China. Virus Research, 2001, 81(1-2): 29-37.
[34]涂长春. 猪瘟国际流行态势、我国现状及防制对策. 中国农业科学, 2003, 36(8): 955-960.
[35]丘惠深, 郎洪武, 王在时. 猪瘟兔化弱毒疫苗与我国近年猪瘟野毒的免疫保护相关性试验. 1997年兽医微生物学学术年会. 1997: 115-117.
[36]王  琴, 宁宜宝. 猪瘟免疫失败的主要原因分析. 猪世界, 2003, (7): 7-9.
[37]Suradhat S, Damrongwatanapokin S. The influence of maternal immunity on the efficacy of a classical swine fever vaccine against classical swine fever virus, genogroup 2.2, infection. Veterinary of Microbiology, 2003, 92(1-2): 187-194.
[38]van Oirschot J T. Vaccinology of classical swine fever: from lab to field. Veterinary of Microbiology, 2003, 96(4): 367-384.
Share on Mendeley
PDF(440 KB)

Collection(s)

Reviews

60

Accesses

0

Citation

Detail
Sections
Recommended

/

〈 〉